AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33438092 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified).
Number of subjects: 124
Study 33438438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary transit time (PTT) from first-pass perfusion imaging
Number of subjects: 410
Study 33438438 — intervention group
Group type: COMPARATOR
Intervention: Normal reference values of PTT in asymptomatic volunteers
Number of subjects: 410
Study 33438438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical cMR parameters including LV and RV ejection fraction or feature tracking global longitudinal strain
Number of subjects: 410
Study 33438477 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 0
Study 33438477 — intervention group
Group type: COMPARATOR
Intervention: Control group (other echinocandins)
Number of subjects: 0
Study 33438658 — intervention group
Group type: EXPERIMENTAL
Intervention: Square wave
Number of subjects: 9
Study 33438658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal wavelet
Number of subjects: 9
Study 33438658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both waveforms
Number of subjects: 9
Study 33438862 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of future relapse include age, intensity of craving, number of standard glasses consumed, psychiatric comorbidity (depression), employment and family/marital status.
Number of subjects: 0
Study 33438862 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predictive of future relapse include consumption of other substances and greater intensity of craving at the time of alcohol withdrawal.
Number of subjects: 0
Study 33439075 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid for Patients and Families
Number of subjects: 0
Study 33439142 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mobile phone app (My Braces)
Number of subjects: 0
Study 33439142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33439382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 0
Study 33439382 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3 inhibitors
Number of subjects: 0
Study 33439382 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced risk stratification and new treatment strategies
Number of subjects: 0
Study 33439463 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-DT vaccine
Number of subjects: 1311
Study 33439583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 33439583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal prohormone of brain natriuretic peptide (NTproBNP)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin T (cTnT-hs)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: growth differentiation factor 15 (GDF-15)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: transmembrane immunoglobulin and mucin domain protein (TIM-1)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: renin
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: osteoprotegerin (OPG)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble suppression of tumorigenesis 2 protein (sST2)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: cystatin-C (Cys-C)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: carbohydrate antigen 125 (CA-125)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: brain natriuretic peptide (BNP)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: interleukin 6 (IL-6)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: hepatocyte growth factor (HGF)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: spondin-1
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: fibroblast growth factor 23 (FGF-23)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: chitinase-3 like protein 1 (CHI3L1)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: tumor necrosis factor receptor 1 (TNF-R1)
Number of subjects: 605
Study 33439866 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenomedullin (AM)
Number of subjects: 605
Study 33440132 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient stroke rehabilitation discharge (DC)
Number of subjects: 89
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of both irritability and ADHD symptoms
Number of subjects: 489
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of irritability and moderate levels of ADHD symptoms
Number of subjects: 489
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate levels of irritability and high levels of ADHD symptoms
Number of subjects: 489
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of both irritability and ADHD symptoms
Number of subjects: 489
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: High overall irritability
Number of subjects: 489
Study 33440203 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately comorbid ADHD symptoms
Number of subjects: 489
Study 33441102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment group (MMSE < 27)
Number of subjects: 164
Study 33441102 — intervention group
Group type: COMPARATOR
Intervention: Control group (MMSE ≥ 27)
Number of subjects: 164
Study 33441102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment measured using age- and education-adjusted MMSE scores
Number of subjects: 164
Study 33441162 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy (SABR)
Number of subjects: 26
Study 33441162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic imaging biomarkers
Number of subjects: 26
Study 33441362 — intervention group
Group type: COMPARATOR
Intervention: Severe haemophilia A and B without prophylaxis
Number of subjects: 240
Study 33441362 — intervention group
Group type: COMPARATOR
Intervention: Mild, moderate, and severe haemophilia A or B with prophylaxis
Number of subjects: 240
Study 33441362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with haemophilia A and B of comparable severity
Number of subjects: 240
Study 33441362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with haemophilia
Number of subjects: 240
Study 33441381 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase, lipase, and trypsinogen levels measured in patients with single-autoantibody positivity.
Number of subjects: 800
Study 33441449 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable genital CT load measured using V-PCR in women with genital CT (n=499)
Number of subjects: 524
Study 33441449 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with urogenital symptoms
Number of subjects: 524
Study 33441449 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with concurrent rectal CT
Number of subjects: 524
Study 33441454 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA-AD
Number of subjects: 31
Study 33441454 — intervention group
Group type: COMPARATOR
Intervention: DAT-AD
Number of subjects: 31
Study 33441669 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% sodium substitute salt for 8 weeks
Number of subjects: 39
Study 33442015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 33442106 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 671
Study 33442108 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observation period (4 weeks)
Number of subjects: 2594
Study 33442108 — intervention group
Group type: COMPARATOR
Intervention: Retrospective observation period (6 months)
Number of subjects: 2594
Study 33442251 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-every-3-months paliperidone palmitate (PP3M)
Number of subjects: 506
Study 33442261 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based self-management training program for peer leaders
Number of subjects: 0
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard coiling
Number of subjects: 1135
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 1135
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysms <10 mm
Number of subjects: 1135
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysms with narrow neck
Number of subjects: 1135
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged <70 years
Number of subjects: 1135
Study 33443137 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (coiling or BAC)
Number of subjects: 1135
Study 33443938 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh procedures
Number of subjects: 44594
Study 33443938 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mesh procedures
Number of subjects: 44594
Study 33443938 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal placement of surgical mesh (TVM) procedures
Number of subjects: 44594
Study 33443938 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy (LSC) procedures
Number of subjects: 44594
Study 33443981 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 100
Study 33443981 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 100
Study 33443981 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study 33444080 — intervention group
Group type: EXPERIMENTAL
Intervention: CARG-BC score risk groups (low, intermediate, high) based on weighted predictors
Number of subjects: 473
Study 33444177 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset diabetes mellitus (DM) screening program
Number of subjects: 0
Study 33444177 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI or endoscopic ultrasound investigation for patients with worrisome features
Number of subjects: 0
Study 33444199 — intervention group
Group type: COMPARATOR
Intervention: Clinical surveillance with placebo (no anticoagulation)
Number of subjects: 0
Study 33444199 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment with rivaroxaban
Number of subjects: 0
Study 33444198 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention (four individual counselling sessions over 12 weeks)
Number of subjects: 0
Study 33444198 — intervention group
Group type: COMPARATOR
Intervention: Control group (one short counselling session at baseline and written information on smoking cessation)
Number of subjects: 0
Study 33444198 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention
Number of subjects: 0
Study 33444198 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention (in a subsample of 80 participants)
Number of subjects: 0
Study 33444268 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 52
Study 33444268 — intervention group
Group type: EXPERIMENTAL
Intervention: B-FFR-500
Number of subjects: 52
Study 33444571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Gastric Cancer Screening
Number of subjects: 0
Study 33444571 — intervention group
Group type: EXPERIMENTAL
Intervention: National Colorectal Cancer Screening Program
Number of subjects: 0
Study 33445053 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloid derived suppressor cells (MDSC)
Number of subjects: 0
Study 33445053 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive tumor microenvironment (TME)
Number of subjects: 0
Study 33445952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical deligation with intravenous recombinant tissue plasminogen activator administered 2 days after deligation
Number of subjects: 291
Study 33445952 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue plasminogen activator administered at day 4
Number of subjects: 291
Study 33445952 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days
Number of subjects: 291
Study 33445991 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 21
Study 33446112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sideways walking intervention for 6 weeks
Number of subjects: 15
Study 33446167 — intervention group
Group type: EXPERIMENTAL
Intervention: PT workshop intervention
Number of subjects: 208
Study 33446655 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine with saponin-based Matrix-M adjuvant
Number of subjects: 0
Study 33446655 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33446895 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP) therapy, 17 sessions, twice weekly
Number of subjects: 41
Study 33446921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose
Number of subjects: 370
Study 33446921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialyllacto-N-tetraose c (LSTc)
Number of subjects: 370
Study 33446921 — intervention group
Group type: COMPARATOR
Intervention: 3'-sialyllactose and LSTc
Number of subjects: 370
Study 33446921 — intervention group
Group type: COMPARATOR
Intervention: Lewis or secretor-dependent HMOs like 2'-fucosyllactose
Number of subjects: 370
Study 33447520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue therapy
Number of subjects: 0
Study 33447520 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33447870 — intervention group
Group type: EXPERIMENTAL
Intervention: Group consultation prior to surgery for colorectal cancer
Number of subjects: 124
Study 33448002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 0
Study 33448002 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 0
Study 33448002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 0
Study 33448286 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) emphasizing parent-led infant-directed singing during NICU hospitalization and across 3 months post-discharge
Number of subjects: 3
Study 33448286 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 3
Study 33448731 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Truvada (HIV preexposure prophylaxis)
Number of subjects: 255
Study 33448881 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing
Number of subjects: 98
Study 33448893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab and bendamustine followed by ofatumumab maintenance
Number of subjects: 49
Study 33448893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance after induction therapy
Number of subjects: 49
Study 33448932 — intervention group
Group type: EXPERIMENTAL
Intervention: SwQoR-LA (Quality of Recovery Scale) via mobile app (RAPP)
Number of subjects: 107
Study 33449073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 158814
Study 33449073 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic Whites
Number of subjects: 158814
Study 33449193 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite restorations placed under general anesthesia
Number of subjects: 101
Study 33449428 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Drug Delivery (TDD) for chronic nonmalignant pain
Number of subjects: 4646
Study 33449578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning interventions for PLWH
Number of subjects: 0
Study 33449605 — intervention group
Group type: EXPERIMENTAL
Intervention: Verification phase (VER) after graded exercise test (GXT)
Number of subjects: 33
Study 33449813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprenetapopt (APR-246) in combination with azacitidine
Number of subjects: 55
Study 33449813 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 55
Study 33449824 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection screening (intervention group)
Number of subjects: 96116
Study 33449824 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 96116
Study 33450010 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode radiofrequency balloon catheter (RFB) for pulmonary vein isolation (PVI)
Number of subjects: 85
Study 33450184 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for mesothelioma after radiotherapy (SMART) protocol including 25 Gy IMRT followed by extrapleural pneumonectomy
Number of subjects: 96
Study 33450184 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for mesothelioma after radiotherapy (SMART) protocol
Number of subjects: 96
Study 33450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe white matter hyperintensities (WMHs), n=86 (41%)
Number of subjects: 210
Study 33450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatments in individuals with cerebral infarct
Number of subjects: 210
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Th1 cells at baseline (CD45RA- CCR6- CXCR3+ CCR4-)
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of Th2 cells (CD45RA- CCR6- CXCR3- CCR4+)
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker score of higher levels of Th1 cells and CD8+ central memory T-cells
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: High TIM3 expression on T-cells
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of phenotypically naive (CCR7+CD45RA+) and effector memory (CCR7-CD45RO+) CD8+ T-cells
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of Th2 cells
Number of subjects: 28
Study 33450703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker score of higher CD19+ and CD8+ cells
Number of subjects: 28
Study 33450821 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33451297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (DEX implant)
Number of subjects: 35
Study 33451313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 1484
Study 33451313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask related side-effects (MRSEs) questionnaires
Number of subjects: 1484
Study 33451780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac® (tri-antigenic recombinant Hepatitis B vaccine)
Number of subjects: 91
Study 33451977 — intervention group
Group type: EXPERIMENTAL
Intervention: TTI-621 (SIRPα-IgG1 Fc)
Number of subjects: 164
Study 33451977 — intervention group
Group type: EXPERIMENTAL
Intervention: TTI-621 combined with rituximab
Number of subjects: 164
Study 33452195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalised children
Number of subjects: 12500
Study 33452195 — intervention group
Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 12500
Study 33452634 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 103
Study 33453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-clinic visits using parentally acquired vital signs and focused echocardiographic images.
Number of subjects: 15
Study 33453199 — intervention group
Group type: COMPARATOR
Intervention: On-site clinic visits (control group).
Number of subjects: 15
Study 33453294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic patients with high levels of Prevotella and TMAO in coronary thrombus
Number of subjects: 146
Study 33453294 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemic patients with low levels of Prevotella and TMAO in coronary thrombus
Number of subjects: 146
Study 33453294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hyperglycemia (≥140 mg/dl)
Number of subjects: 146
Study 33453294 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal glucose levels (<140 mg/dl)
Number of subjects: 146
Study 33454126 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe migraine participants
Number of subjects: 23
Study 33454128 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate measurement in ICU patients
Number of subjects: 909
Study 33454128 — intervention group
Group type: COMPARATOR
Intervention: Treatment protocol for phosphate repletion
Number of subjects: 909
Study 33454128 — intervention group
Group type: COMPARATOR
Intervention: Phosphate repletion in HypoP patients
Number of subjects: 909
Study 33454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Topological Data Analysis (TDA) of quantitative coronary plaque characteristics on coronary CTA
Number of subjects: 1264
Study 33454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (identified by TDA)
Number of subjects: 1264
Study 33454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient similarity network by TDA
Number of subjects: 1264
Study 33454291 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo aspiration system
Number of subjects: 119
Study 33454601 — intervention group
Group type: EXPERIMENTAL
Intervention: MOG-ab testing in AQP4-ab-negative patients
Number of subjects: 67
Study 33454601 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic neuritis as a symptom
Number of subjects: 67
Study 33454601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging findings
Number of subjects: 67
Study 33454601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressant treatments
Number of subjects: 67